PAR6 MODELING THE IMPACT OF PATIENT AND CLINICAL HETEROGENEITIES ON THE COST-EFFECTIVENESS OF SELECTIVE COX-2 INHIBITORS SUCH AS LUMIRACOXIB AND CONVENTIONAL NSAIDS IN PATIENTS WITH OSTEOARTHRITIS

Article OPEN
Huels, J; Wright, A; Kahler, K; Omar, M; Dubois, RW; Chiou, CF; Doan, OV;
(2006)
Share - Bookmark